This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This FOA is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)
HHS-NIH11
Administering federal agency
Fiscal Year
2023
Estimated Funding
$0
Estimated Award Date
Jul 01, 2023 12:00:00 AM EDT
Estimated Project Start
Jul 10, 2023 12:00:00 AM EDT